biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by neinsteinon Mar 07, 2017 10:58pm

196 Views

Post# 25948401

RE:RE:My Take

" is testing in mice enough to be truly compelling if that is all that's been done? "

If this is representaive of your level of knowledge about the development of transcendpep my best advice you is to stop posting and either try very hard to learn what has been going on or just sit back and enjoy the ride. You are, respectfully, so far out of the loop that anything you post - save the current time or temperature - is so lacking in knowledge it should be embarrassing.

Bullboard Posts

Eminent acquires promising Nevada gold project